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1. Introduction
Microarray technology developed in the late 1990’s allows one to simultaneously analyze the
entire transcriptome of a given population of cells at a single time. It is essentially a microchip
with each spot containing about a picogram of DNA immobilized at defined locations. This
DNA captures mRNA or cDNA from defined cell populations (tissue, cell line, etc) in a
quantitative manner. This technique allows complex patterns of global gene expressions to be
quickly and easily detected between two specimens. Microarrays were initially used to
describe cell cycle patterns of Saccharomyces cerevisiae [1]. Its powerful potential was quickly
recognized and applied towards cancer. The first successful application of this technology was
to show that diffuse large cell B lymphomas had two different subtypes. One subset of this
cancer was easily treatable with chemotherapy; whereas, the second phenotype required a
more aggressive therapy [2].
Microarray analysis of human GBM quickly revealed that this cancer could be divided into
three different subtypes: neural/pro-neural, mesenchymal and classical GBM [3]. Each subset
has its own unique profile of gene expression along with a unique survival pattern. The
microarray data also represents a composite of the tumor and the surrounding non-cancerous
cells that are involved in the microenvironment including host immune cells. Microarrays have
also recently provided possible mechanisms that GBM have used to avoid the effects of anti-
angiogenic therapies [4]. Thus, this in silico technology offers new strategies to target various
cancers in still many unknown ways.
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In 2005 the National Cancer Institute and the National Institute of Neurological Disorders and
Stroke (NINDS) initiated the REMBRANDT (REpository for Molecular BRAin Neoplasia DaTa
(http://rembrandt.nci.nih.gov/) database. This informatics venture originated from the
leadership of Dr. Subhashree Madhaven (NCI Center for Bioinformatics) and Dr. Howard Fine
(Glioma Molecular Diagnostic Initiative at the Center of Cancer Research). Currently this
research portal molecularly characterizes a large number of primary brain tumors and
correlates this gene expression, copy number data with patient survival. At this time, there are
several active collaborators who are supplying information into this database: Henry Ford
Institute (Detroit), Johns Hopkins University (Baltimore), National Cancer Institute-Neuro-
Oncology Branch, National Institute of Neurological Disorders and Stroke (NINDS), M.D.
Anderson Cancer Center (Houston), Mofitt Cancer Center (Tampa), Thomas Jefferson
(Philadelphia), Univ. of California, Los Angeles, Univ. of California, San Francisco, Univ. of
Pittsburgh Medical Center, and Univ. of Wisconsin Carbone Cancer Center (Madison). At the
time of writing this chapter 568 brain cancer specimens are available for gene expression
analysis, while 552 patients were analyzed (May-Aug 2012) for copy number studies using
REMBRANDT version 1.5.5. Thus, we have a relatively large database for which we can draw
good information to determine the usefulness of targeting any given gene of interest towards
a given brain cancer.
Van der Bruggen, et al., [5] compiled a listing of various tumor antigens that have been found
within various human cancers. Tumor antigens can be defined as either being tumor-specific
or tumor-associated. These tumor-associated antigens are composed of mutations, shared
tumor-specific, differentiation and over-expressed antigens. Tumor specific antigens are
actually quite rare. The epidermal growth factor receptor variant III (EGFRvIII) is an example
of a glioma-specific tumor antigen. Most antigens used for cancer therapy are shared antigens,
in which the cancers over-express these proteins. By this definition most antigens should be
described as cancer-associated antigens, as opposed to cancer-specific antigens. When tumor
antigens are discovered, either by molecular techniques or using immunological techniques,
only a handful of tumor cases are actually evaluated to generate the initial scientific report.
Hence the real scope of the true expression pattern was usually limited due to a small sampling
size of the initial report. Analyzing large databases are perhaps the best way to validate the
universal nature of any tumor antigen.
Traditionally, there are antibody-based or cell-mediated-based antigens. Back in the
1970’s-1980’s, antibody responses were viewed as the best way to treat tumors. These anti‐
bodies need to be specifically designed to bind to cancer-specific cell surface proteins. Anti‐
bodies have been detected coming from glioma patients (PHD finger proteins-3 and -20 were
identified [6, 7]. When these were evaluated by REMBRANDT, there were only 1 and 5 patients
who over-expressed these respective transcripts and there were no statistical significance.
Many antibodies were designed against glioma cells. Antibodies targeting internal antigens
will obviously not be clinically applicable, since these antibodies’ binding regions can’t access
their targeted intracellular epitopes. Antibodies with 150,000 dalton molecular weighs can’t
penetrate deeply into intracellular tumor cells due to their inability to cross cell-adhesion
junctions between adjacent cells. Peripherally located tumor cells usually bind the most
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amount of antibody, leaving the more internally located ones less affected. Single chain
variable antibody fragments (scFv) are being developed out of monoclonal antibody technol‐
ogy can penetrate deeper into tumor beds, since they have lowered molecular weights (about
15-20 kd). ScFv targeting EGFRvIII, MRP3, TRAIL and c-Met have been used in preclinical
models of human gliomas [8-11]. But just like regular antibodies, the scFv will undoubtedly
predominantly bind to peripheral tumor cells. The clinical efficacy of scFv still has not been
firmly established.
In contrast, internal and external antigens can be processed by intracellular proteosome using
a universal ubiquitization pathway. Eventually some of these antigenic peptides are presented
on the cell-surface of major histocompatibility (MHC) molecules, provided they have the right
affinity and the right concentration. So once the correct anti-cancer T cells are activated towards
these peptides, the T cells can respond to multiple tumor cells. The caveat to this approach is
that many tumor cells down-regulate their MHC expression, making themselves “invisible”
to the T cells. The use of dendritic cell (DC)-based vaccines to generate endogenous T cells in
vivo seems to show that T cell-induced therapies are a better way to treat gliomas than humoral
approaches [12]. Prins, et al, [13] showed that DC-based therapy using the autologous tumor
to prime the T cells works better against the mesenchymal type of GBM than the other two
subsets. So the identification of the right tumor antigens that glioma cells possess is the Holy
Grail of tumor immunotherapy.
2. Hallmarks of cancer
In 2012 Hanahan and Weinburg updated their classic “Hallmarks of Cancer” paper where they
described the original six Hallmarks (resisting cell death, sustained proliferation, evading
growth suppression, activating invasion and metastasis, enabling replicative immortality and
inducing angiogenesis) with two more emerging Hallmarks (deregulating energetic and
avoiding immune destruction), along with two enabling characteristics (genomic instability
and mutation and tumor promoting inflammation) [14]. Hanahan and Weinburg pointed out
that various anti-cancer therapies currently being developed actually target one of these
possible ten Hallmarks of Cancer. Each of these drugs is designed to be very specific and only
affect a certain cancer pathway. Hence these drugs should avoid any unwanted side effects.
One obvious down-side to this way is that cancers are very resourceful and can quickly mutate
to avoid the actions of this drug.
They also speculated that if you design a drug that targets two or more of these pathways,
then that drug should then theoretically be more potent than a drug that targets a single
“Hallmark”. We think it is possible to simultaneously target multiple “Hallmarks”. A whole
tumor cell vaccine which targets a wide variety of possible “Hallmarks” is possible.
Figure 1 shows some representative glioma antigens that are known and can induce immune
responses against seven of the “Hallmarks”. So the true power of tumor vaccines using whole
cells as the source of the vaccine might be that it targets multiple proposed Hallmarks of Cancer
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at once. So finding newer antigens that might additionally target different Hallmarks could
also improve immunotherapy.
Figure 1. Whole tumor vaccines can target multiple Hallmarks of Cancer. Listed are some glioma tumor-associated
antigens which can be classified under the various categories of the Hallmarks of cancer.
3. Current glioma associated tumor antigens: How well do our current
tumor antigens fit the survival data of GBM?
REMBRANDT is quite easy to use. One can access the data of all glioma types or limit the
selection of brain cancers to GBM, mixed gliomas, or oligodendroglioma. At the gene expres‐
sion level, one can concentrate on over-expression that is 2.0-fold better than control samples,
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or under expression < 0.5-fold expression, or an intermediate expression pattern. For this
chapter we will be examining the universal nature of all glioma types. If readers want more
specific brain cancer subtypes, they can easily study the various subsets of brain tumors on
their own using REMBRANDT.
Previously,  many tumor antigens  used for  glioma immunotherapy have been described
[15-20].  A good tumor-associated antigen is  one that  is  found in a large number of  hu‐
man  glioma  patients  and  has  many  different  epitopes,  so  that  many  different  T  cell
clones  can  respond to  it,  regardless  of  the  major  histocompatibility  complex  haplotype.
The targeted antigen should also be associated with a poor prognosis. Therefore proper‐
ly targeting this antigen interferes with some key glioma cell  function; i.e.,  cell  division,
growth factor  signaling,  migration and other  processes  of  the Hallmarks of  Cancer.  Im‐
proved patient survival if  a successful therapy was mounted against this tumor antigen,
should  also  eliminate  those  antigen-positive  cells.  By  changing  the  tumor  population
from  an  antigen-positive  one,  to  an  antigen-negative  one,  overall  survival  should  im‐
prove, if that antigen/protein was indeed critical to glioma biology. Even at this time, we
still  don’t precisely know what the best glioma-specific antigens are to use for immuno‐
therapy, except by doing expensive clinical trials. The other theoretical possibility, is that
the antigen must be found on every tumor cell. In which case, every antigen-positive cell
needs  to  be  eliminated.  In  which  case,  every  antigen  is  created  equally.  This  question
will eventually need to be answered, before immunotherapeutic cures can become a real‐
ity. Our own speculation is that not all glioma-associated antigens are equally useful.
When the currently known glioma-associated tumor antigens are subjected to REMBRANDT
analysis, some of these antigens do seem to show a good inverse correlation with survival.
Having more of the antigen does seem to correlate with a poorer survival in a dose-dependent
manner. Figure 2 shows a representative illustration of this effect using the well-known
glioma-associated antigen, IL13Rα2. There were 121 patients (red) who possessed elevated
IL13Rα2 mRNA levels (21% of all glioma patients), while 115 (20% of all gliomas examined)
had down-regulated IL13Rα2 expression (green). The more IL13Rα2 mRNA the patient’s
glioma had, the poorer the prognosis of these patients was. This data can be considered as a
dose response experiment. By the Log-rank test, provided by REMBRANDT, these values were
quite statistically significant from the total 568 glioma patients (blue) that were examined.
Thus, this tumor antigen should be good one to target for a subset of glioma patients, since the
lower the expression of IL13Rα2 lead to better patient survival. Other very good glioma-
associated antigens are: EphA2, FABP7, FosL1, MRP-3, NR2E1 and podoplanin (Table 1).
Some antigens such as survivin/Birc5, CD133, her2 and Sart-2 were considered good antigens
in that either their over-expression lead to poor survival or their under-expression had a better
prognosis. This observation could be that some samples didn’t have sufficient samples to
provide a statistical significant value. WT1 also seems to be a good target. In an early clinical
trial using WT-1 peptide vaccinated patients, there was some survival benefit for the first 100
weeks after the vaccination [21]. Thus, an early test of our hypothesis seems at first glance to
be a viable one.
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Very Good Antigens Good Antigens Poor Antigens
BCAN,CHI3L2,
EphA2,FABP7, FosL1,
IL-13Rα2, MRP3, NR2E1,
PDPN, YKL-40/CHI3L1
B3GALNT/Galt3, CD133, Her2,
IGF2BP3, Sart-2, Survivin, WT-1
Art-1, Art-4, ARF4L/ARL4D, CLIP2, CSPG4,EphB6,
EZH2, Gnt-V, GP100, KIF1C, KIF3C, HNRPL, livin,
Mage-A1, MELK, NES, NLGN4X, NRCAM, PHF-3,
PHF-20, Prame, PTH-rP, PTPRZ1, Sart-1, Sart-3,
SLC01C1, Sox-2, Sox-6, Sox-10, Sox-11, SSX2, TNC,
Tert, Trp-2/DCT, Tyrosinase, Whsc2
Very Good Antigens: both over-expression predicts shorter patient survival and under-expression leads to longer
survival rates. Statistical significance reached by REMBRANDT.
Good Antigens: one value (over-expression or under-expression) achieved statistical significance.
Poor Antigens: Neither over- nor under-expression correlated with patient survival and had any statistical
significance.
Table 1. Currently known Glioma-associated antigens and their predicted usefulness against all gliomas as predicted
by REMBRANDT.
Unfortunately,  most  reported glioma-associated antigens  such as  Sox2,  Sart3,  etc  do not
seem to have any prognostic value.  Their expression profile does not indicate any posi‐
tive or negative effect. From this we would conclude, even though the glioma cells carry
this tumor antigen, and in vitro  experiments suggest that CTLs can kill tumor cells bear‐
ing this specific antigen, this antigen does not appear to have any selective or predictive
advantage.  Therefore even if  a  robust  immune response were mounted in vivo  by some
vaccination  or  therapeutic  process,  chances  are  this  response  will  not  produce  any  de‐
monstrable effect, unless all of those antigen-positive tumor cells were eliminated. There‐
fore, just because CTLs can be generated against tumor cells doesn’t necessarily mean it
will produce any clinical response, unless every tumor cell was eliminated. Killing every
tumor within any cancer is highly doubtful.
In conclusion,  some of  our currently known tumor-associated antigens found in human
glioma are still good ones to target by therapeutic interventions including immunological
ones,  while  others  probably  will  not  be  that  much  in  helping  eliminate  this  cancer.
Searching out new target antigens is  still  a  vital  goal  of  immunotherapy and new strat‐
egies to find more appropriate antigens are required. This may be where REMBRANDT
can come in quite handy in developing intelligent rationales for designing better targets
for future immunotherapy (see below).
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Figure 2. REMBRANDT survival of all gliomas showing differential IL13Rα2 expression. The blue symbols show the sur‐
vival of all glioma patients. The red lines show the survival of IL13Rα2 over-expressing gliomas. While the green sym‐
bols show the patients that survived with a low expression of IL13Rα2. Both populations were statistically significantly
different (asterisks) from the majority of all gliomas (blue).
4. Cells of the immune system involved in glioma
The immune system plays an important role in combating a wide variety of pathogens ranging
from viruses, bacteria, fungi, parasites and others. Cancers can also be considered a type of
pathogen that the body must rid itself of on a routine basis. In the mid-1980’s, CD4+ T cell
clones were classified into various subsets of T helper cells, Th1 cells produced cytokines that
stimulated cell-mediated functions, while Th2 cells produced humoral immune responses [22].
New CD4 T helper subsets are still being discovered. Th9, Th17, Th22, Tfh and Treg are
populations recently described in the last several years. Each subset seems to have its own
niche with regards to certain immunological functions controlling certain pathogens or
antigens. Besides CD4+ T cells, CD8, NK, and γδ T cells all play roles in tumor immunity.
Figure 3 shows these various subsets that are currently known along with some of their
postulated effector cytokines. By REMBRANDT, we tried to analyze these different T cell
subtypes. We examined their respective cytokine(s), possible effector molecules or putative
transcription factors that control the transcription of these cell types.
REMBRANDT surprisingly revealed that CD4 expression had a bad prognosis for glioma
patients. Over-expression of CD4 had a statistically significant poor survival prognosis, while
an under-expression trended towards better survival, but this last condition was not consid‐
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ered significant (p=0.10). Naïve CD4+ T helper cells can give rise to numerous subtypes of
CD4+ T cells: Th1, Th2, Th9, Th17, Th22, Tfh, and Treg. Thus, the sum total of all these CD4
subsets represents this poor overall survival.
Figure 3. The cells of the Immune system and how they mediate some of their functions. Lymphocyte precursors give
rise to either CD4+ or CD8/NK precursors. As a result of T cell receptor engagement along with the presence of cyto‐
kines shown in the rectangles can give rise to various T helper subsets. After the Th subsets are restimulated they can
then release various cytokines as shown in the polygons. These cytokines can either affect the glioma or the cells in the
local microenvironment. CD8/NK precursors can differentiate into either NK, γδ, or CD8 T cells. These cells can either
kill tumor cells directly or via other undefined pathways.
In has been generally acknowledged that Th1 cells produce cell-mediated immunity that
results in effective anti-tumor immune responses. Th1 cells tend to release cytokines such as
IL2, IFN-γ, TNFα and LT, that either work directly on the tumor or indirectly by stimulating
effector anti-tumoricidal cells, CTLs, NK, macrophages, etc. REMBRANDT suggested the
expression of IL2 portrays a slightly better survival when these cytokines were elevated in
patients but these were not significant. IFN-γ over-expression produced statistically significant
positive outcomes while TNF down regulation lead to a worse survival. Three transcription
factors, t-bet (TBX21), Signal Transducer and Activator of Transcription factor-1 and -4, Stat1
and Stat4, respectively regulate Th1 cell functions. T-bet and Stat-4 failed to show any
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significance. Stat1 showed a poorer survival, but we can’t eliminate the possibility that glioma
cells themselves directly utilize stat1 [23]. Thus, the classic Th1 cells where all Th1 associated
cytokines and transcription factors that are simultaneously made, were not really displayed
within human clinical gliomas.
Th2 cells are classified by their production of the cytokines IL3, IL4, IL5, IL6, IL10, IL13, and
IL25. Interleukins 3, 4, 10 and 13 failed to show any significant relationship with glioma survi‐
vorship. The over-expression of IL6 and IL25 lead to poor patient survival, while over-expres‐
sion of IL5 forecast better survival of glioma patients. Looking at the transcription factors that
control the fate of Th2 (Gata-3, Stat6, Stat5 and MAF) also displayed a mixed effect. Stat6 was
not significant, while Stat5, and MAF correlated with poorer survival. Again the secretion pro‐
files predicted by current dogma within in situ Th2 cells gliomas are not consistent with cur‐
rent experimental conclusions about Th2 cells and their global cytokine expression pattern.
A few not so well known T helper subsets (Th9, Th22 and Tfh cells) are easily studied by
microarray analyses. As a result of exposure to antigen with IL4 and TGF-β, Th9 cells can be
generated. Th9 can release IL9 and IL10. As described above for these cells, IL10 didn’t have
any relationship with glioma survival. IL9 had a mixed expression, both under-expression and
over-expression both had poor prognoses. Hence Th9 cells probably do not play an important
role in glioma immunology. Th22 cells are induced after antigen exposure when IL6 and TNF
are also present. These cells produce IL13 and IL22. Both cytokines appeared to be devoid of
any significance, so the contributions of Th22 are probably minor. Tfh (follicular helper) cells
are stimulated by IL6, IL21 and IL27. Tfh produce IL6, IL10 and IL21. Both IL6 and IL21 lead
towards poor survival. Thus, Tfh cells are suspicious and may contribute to the poor response
of CD4+ cells in glioma patients.
Treg cells are currently in vogue explaining poor anti-tumor immunity in many tumors
including gliomas [24]. TGF-β and IL2 drive the appearance of Treg. IL2 as mentioned earlier,
trends towards a favorable patient survival, however the IL2Rα (CD25) gene didn’t show any
significant relationship contradicting the current dogma that IL2Rα+ Treg are as predominant
in GBM as previously thought [25]. The presence of TGF-β1 and TGF–β2 mRNA showed a
very poor survival, glioma cells do make TGF-β1 and TGF-β2, so the initial source of stimu‐
lation of Treg may come directly from the glioma cells. Upon stimulation with TGF-β, the Treg
can also release this cytokine or express the membrane form of TGF-β and thus amplifies the
glioma’s immunosuppressive nature. Treg use the FoxP3, Smad3 and Stat5 transcription
factors. Stat5 and Smad3 showed a correlation with poor patient survival, but gliomas can also
use smad3 and Stat5 [26,27], so the contribution of these transcription factors from Treg can’t
truly be assessed. FoxP3 is thought to be very specific for Treg, but it’s presence within gliomas
actually failed to show any significant correlation with patient survival. IL10 is released by
Treg in vitro, but REMBRANDT doesn’t show any survival relationship of IL10 production
with gliomas, as described with Th2 and Th9 cells. The various mechanisms by which Treg
can inhibit the immune system will be described in the next section (see Section 5: Immuno‐
supression). Thus, the previously held belief that Treg are solely responsible for poor patient
performance via various immunotherapies, needs a critical reassessment.
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Th17 cells type also uses TGF-β to help drive their initial activation. In addition, these Th17
precursor cells require IL6, IL21, IL1α and IL1β to become polarized into the Th17 phenotype
after the initial T cell receptor engagements. IL6 and IL21 over-expression correlated with poor
patient survival, while the expression of IL1α or IL1β subtypes didn’t. Th17 cells have been
identified in gliomas [28], but their precise role isn’t defined. For melanomas, Th17 cells can
mediate tumor destruction [29], but in colon cancer Th17 helps tumors grow [30]. REM‐
BRANDT analysis of the transcription factors used by Th17: RORC (RORγT), RORA (RORα)
and Stat3 did not show any positive or negative effects. Th17 cells release IL17A, IL17F, IL22,
IL21 and IL26. The first three cytokines fail to correlate with patient survival. IL21 does show
a poor patient survival prognosis, while IL26 shows a better patient survival. So the final
verdict about Th17 cell’s role in glioma is still undecided.
In conclusion, our current understandings of Th helper subsets seem to show multiple
cytokines being expressed by cloned cells in vitro. However these distinct subsets can not be
firmly identified in situ. This complexity is probably due to the complex cytokine/growth
factor/environmental factors being produced within the tumor by the tumor, Treg or immune
cells. One might even have to postulate subsets of these cells; e.g. Th1.1, Th1.2, Th2.1, Th2.2,
Treg1.1, Treg 1.2, etc to explain these empirical observations. As described earlier, activated
dendritic cell vaccines pulsed with autologous GBM tumors do improve GBM survival, so it
will be important to describe what cytokines or subsets are correlating in those patients that
are positively responding to such therapies.
CD8a is a more promiscuous marker, since it can be found on CTLs, NK, DC and other cell
types. CD8b expression is exclusively found on CTLs; there were only 11 patients which over-
expressed CD8b, while 89 patients down-regulated CD8b. The down-regulation of CD8b did
however have a poor survival although not significant. Eosmesdermin (Eomes) is a transcrip‐
tion factor reported to control CTL function [31]. There was trend towards lower Eomes
expression with longer patient survival occurred in 11 patients. Twenty patients over-
expressed this gene, but this profile didn’t alter patient survival when compared to all glioma
patients. Hence, the evidence for a beneficial role of CTLs in situ seems to be weak.
NK cells and γδ type T cells are innate immunity-based lymphocytes. We examined a couple
of NK/ γδ related genes [32]: NKG2D (KLRK1) and NKp30 (NCR3). Both of these genes when
they were down-regulated lead to poor survival. Conversely, when patients presented higher
expression, this produced a better survival. Both findings had statistical significance. Thus,
these innate type immune cells seem to show a dose-dependent in vivo effectiveness. This at
first glance seemed unexpected. Two targets of γδ type T cells are the MICA and MICB
molecules [32]. Both of these molecules when over-expressed in glioma had poor prognoses,
while low expressing gliomas had better outcomes. Hence the use of γδ type T cells to treat
gliomas might be a good clinical approach [33-35]. CTLs, NK and γδ T cells use perforin (PRF1)
and granzymes A and B (GRMA and GRMB) to actively lyse tumor targets in vitro. None of
these gene expression patterns was associated with beneficial or deleterious effects. The exact
mechanism by which NK/ γδ type T cells could have anti-glioma tumor effects is still unknown.
This anti-tumor immunity might not actually be mediated through direct cell-mediated
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cytotoxicity using perforin and granzymes but could be through the release of unknown
cytokines or other unknown effector molecules.
One thing that can be concluded from this REMBRANDT analysis dealing with current tumor
immunity is the in situ process is much more complicated than was previously concluded from
experimental in vitro conditions. Hence new tools need to be developed to explore the anti-
tumor mechanisms that are present within the in situ tumor.
5. Immunosuppression
It has been known for awhile, that advanced cancer patients, including gliomas, have abnormal
and diminished immune responses [36]. This impediment undoubtedly prevents the success‐
ful application of any cellular immunotherapeutic modality and helps explain the complex T
cell immune responses described above. Over the years, it has postulated that a wide range of
cytokines, growth factors and micro-environmental factors (hypoxia, reactive oxygen and
nitrogen) lead to diminished immunological responses [15,37,38]. Figure 4 shows these
potential causes of glioma/immune suppression pathways that have been postulated over the
years. Besides immunosuppressive molecules such as transforming growth factor-β subtypes
1-3 (TGF-β subtypes 1-3), interleukin-10 (IL-10), vascular endothelial cell growth factor (VEGF)
or prostaglandin E (PGE), there are also suppressor cells such as T regulatory cells (Treg) and
myeloid derived suppressor cells (MDSC) that contributes to the overall immunosuppressive
microenvironment.
REMBRANDT data analysis does show that some cytokines/growth factors have good
statistical inverse correlations with patient survival. TGF-β1 and TGF-β2 inversely correlate
with patient survival in a dose-dependent manner (high expression correlated with poor
survival, while low expression prognosticated a better survival). TGF-β3 doesn’t appear to
play much of a significant role within glioma patients. Interleukin-10 previously considered
to play a major role in immunosuppression doesn’t seem to have that much of an effect as seen
above with the Th2 and Th9 phenotypes. VEGF inhibits immune activity via inhibitory actions
upon dendritic cells [39]. Immune responses within the brain are initiated by the local dendritic
cells [40].Both VEGF-A and VEGF-B over-expression significantly correlated with poor patient
survival, while VEGF-C and VEGF-D failed to show any deleterious behavior. Thus, VEGF-A
and VEGF-B besides promoting angiogenesis of brain cancers promotes immune suppression.
Treg and MDSC suppress the immune system through different mechanisms. Treg can release
TGF-β or express cell surface TGF-β (as described above). Treg can release indoleamine-
oxidase-1 (Ido-1) in various tumor models [41]. Ido-1 helps degrade the amino acid, trypto‐
phan. T cells are very sensitive to tryptophan deprivation and become inactivated by this
condition. REMBRANDT shows a significant detrimental effect when IDO-1 is over-expressed,
while in those patients showing reduced expression of IDO-1 a better survival was seen. In
both cases, this data was significant. Human GBM cell lines don’t seem to make Ido-1, so the
contribution of Ido-1 is probably from the Treg. Cytotoxic T lymphocyte antigen-4 (CTLA-4),
Programmed Cell Death-1 (PCD-1), Fas Ligand (FasL), B7-H1, B7-H3 molecules which are
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membrane molecules and can inhibit other effector lymphocytes are possible immunosup‐
pressive pathways of Treg. PCD1 over-expression was not associated with diminished
survival, but under-expression did statistically show improved survival in a cohort of 104
patients. FasL and B7-H1 didn’t show any survival effect, and are probably eliminated in their
role in glioma immunology. B7-H3 was over-expressed in 203 patients and did inversely
correlate with survival in a statistically significant way. There are currently thought to be two
types of Treg, the natural and induced Treg subpopulations. When we examined the cell
surface markers for either induced or natural Treg, nothing was immediately obvious. We
postulate that in situ glioma Tregs are Foxp3-, FasL-, TGF-β+, Ido1+, PCD1+ and B7-H3+ based
upon evaluation by REMBRANDT.
Figure 4. Mechanisms of immunosuppression found within gliomas. As a result of the glioma cell release growth fac‐
tors and cytokines T regulatory (Treg) and myeloid derived suppressor cells (MDSC) are recruited. Glioma cells can ex‐
press membrane proteins Fas Ligand and B7-H3. For sake of simplicity only 1 transmembrane protein is shown.
Likewise Treg can express transmembrane inhibitory molecules FasL, CTLA4, B7-H3 and PCD1. A Red X indicates the
pathways by REMBRANDT analysis are not likely playing a major role pathways. MDSC and gliomas can release Cox 1.
MDSC can either be composed of CD33+ cells or CD14+ cells [42]. These markers can be found
on either the granulocytic or monocytic types of MDSC. MDSC are stimulated by a wide variety
of cytokines and growth factors found in gliomas: GM-CSF, M-CSF, VEGF, IL1, IL4, IL6, IL13
and PGE, most of these cytokines were over-expressed by gliomas as determined by REM‐
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BRANDT. Fifty glioma patients did demonstrate an earlier demise when CD33 was deter‐
mined to be over-expressed. In contrast only 8 patients down-regulated expression of CD33;
this observation was not considered significant. CD14 expression was increased in 186 patients
and possessed significantly shortened lives. Seventeen glioma patients were CD14 down-
regulated and were approaching a significant survival advantage (p=0.058). So both types of
MDSC can reside within human gliomas. MDSC can release TGF-β, arginase or prostaglandin
(PGE) that prevents T cell expansion through different pathways [42]. As described above TGF-
β1 and TGF-β2 are inversely correlated with glioma survival. But TGF-β can come from either
Treg, the glioma itself or from MDSC. Arginase suppresses T cell function in a manner similar
to IDO, in that T cells also require sufficient arginine for proper function. Two isoforms of
arginase are known, Arg-1 and Arg-2. Arg-1 is a cytoplasmic enzyme; Arg-2 is a mitochondria
contained enzyme. Neither form of arginase had any significant effect, eliminating this likely
pathway from occurring in human gliomas. Thus, the way that MDSC mediate their actions
is probably through TGF-β or PGE.
 
Figure 5. Survival statistics of glioma patients with Cox 1 and Cox 2 differential gene expression using REMBRANDT.
The Left Panel shows the survival statistics of glioma patient analyzed for Cox 1 expression. There were 9 patient un‐
der-expressing Cox 1, which failed to achieve statistical significance. Eighty-four patients over-expressed Cox 1, which
did reach a significant p value. The Right panel shows the REMBRANDT analysis of Cox 2 expression. There were 205
patients that under-expressed Cox 2, while only 27 patients over-expressed the Cox 2 transcripts. Neither phenotypes
were considered significantly different from the total population of gliomas.
PGE2 is synthesized by either the cyclo-oxygenase-1 (Cox-1) or -2 (Cox-2) enzymes [43]. Cox
1 is considered by some to be a house-keeping gene and is constitutively produced and
synthesizes low amounts of PGE2. Figure 5 shows the REMBRANDT data dealing with the
cyclo-oxygenases. Cox-2 is inducible and produces much more PGE2 when cells are properly
activated. Many tumors [43], including glioma cells [44,45] are reported to over-express the
Cox2 enzyme. Cox2 derived epitopes have been described in human esophageal cancers that
CTLs can recognize [46], so this enzyme might be a potential human glioma antigen, too.
Epidemiological studies have shown that a daily dose of aspirin helps reduce PGE2 production
and lowers the incidence of a variety of cancers [47]. When Cox2 was analyzed by REM‐
BRANDT, there was an association showing that gliomas that over-expressed Cox2 (27
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patients) showed an unfavorable survival, while the under-expression of Cox 2 in 205 patients
had only slightly improved patient survival. Neither of these expression patterns showed
statistical significance when compared to all gliomas. Cox2 production of PGE might not
therefore be a major source of PGE production as previously thought. When Cox1 expression
was examined as a control, a surprisingly better correlation was found with patient survival.
There were only 5 patients who under-expressed Cox 1, so statistically, this is not considered
significant. Eighty-four glioma patients who over-expressed Cox1 succumbed earlier to their
cancer. This later group of patients did achieve a very good statistical significance (p = 2.8x10-6).
PGE2 is a vasodilator and it is involved in angiogenesis so it may have multiple roles in glioma
biology, besides immune suppression. Only prostaglandin receptors EP2 and EP4 were
elevated within human gliomas using REMBRANDT. Based upon this REMBRANDT
assessment, the role of Cox-1 needs to be investigated further in glioma biology and could be
a target for therapy in some patients.
6. Growth factors, cytokines, chemokine are there targets of
immunotherapy by T cells
PGE2 receptors are coupled to G-proteins that activate adenylate cyclase, leading to an increase
of intracellular cAMP which activates protein kinase A (PKA). This cellular signaling results
in increased production of Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast
Growth Factor (bFGF) that assists new blood vessel formation (angiogenesis) (Figure 6).
Glioma cells also possess growth factor and cytokine receptors, such as the interleukin-13Rα
2 (IL-13Rα2) [48], EphA2 [49], platelet derived growth factor receptor (PDGFR2) [50,51],
epidermal growth factor receptor (EGFR)[52], insulin-like growth factor receptor (IGFR)[53],
c-met (which binds hepatocyte growth factor/ scatter factor (HGF/SF)[54], interleukin-6
receptors (IL-6R) [55], and GM-CSF receptors [56]. Table 2 summarizes this data of growth
factors/cytokines expressed within human gliomas along with their respective receptors. It can
be speculated that some glioma cells use these potential autocrine growth pathways. REM‐
BRANDT does seem to indicate that PDGF-B and PDGFR2 and the IL6/IL6R pathways are
viable models of this autocrine process. The other cytokine/growth factors could be indicative
of paracrine routes. Upon proper binding to their receptors, most growth factors/cytokines
(EGF, IGF, PDGF, FGF, HGF/SF, Ephrin A, IL-6, IL-13 and others) use the PI3 kinase family of
signal transducing docking molecules [57,58].
Upon ligation of the receptor, the Rac, Ras and Raf1 docking proteins are interacting and
activate PI3K. H-ras and N-Ras have a positive correlation with poor glioma survival. Members
of the Ras family, rab4,5,8,11,21,25, have been investigated with multiple aspects of signal
transduction with glioma cells. But REMBRANDT showed that these rabs didn’t have any
significance. PI3 kinase family members do have a strong linkage with poor glioma survival
by our analysis of the current data. Akt1 or Akt2 is also activated and does also show the same
inverse relationship with patient survival. Thus, targeting PI3K/Akt dependent pathways are
still a valid target.
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Figure 6. Generalized mechanism by which growth factor/cytokine interactions can initiate down-stream biochemical
pathways. Upon binding a growth factor or cytokines, Ras/Raf/Rac signal transduction begins. PI3 kinase converts
PIP2 into PIP3. PIP3 stimulates PDK1 which in turn activates Akt. eNOS is turned on by Akt. The asterisks indicate that
protein is over-expressed and leads to poor patient survival by REMBRANDT.
The normal brain contains a variety of neurons, Schwann cells, glial cells, microglia and other
cells. These cells are held in place and are embedded by an extracellular matrix (ECM)[59,60].
Matrix proteins besides providing cell anchorage, can also bind and sequester various soluble
biological modulators. Table 3 also lists the various extracellular matrix proteins found within
the brain that can bind to various glioma-related cytokines/growth factors. Several growth
factors upon binding to their extracellular matrix enhance binding affinity to their receptors.
Since the soluble factor is tethered to a large matrix protein, endocytosis may be slowed and
allowed for increased intracellular signaling to be mediated. A prolonged signal transduction
via PIP3 can also recruits intracellular cytoskeletal elements Wave/WASP-like proteins which
allows actin polymerization to be initiated at this membrane site, this can then help explain
the presence of filopodia, lamellopodia, microvilli and invadopodia of gliomas [61-64]. See
Section 7.2.
7. Mechanisms of invasion of gliomas
7.1. Extracellular mechanisms
It has been concluded that the reason why many human gliomas cannot be cured by con‐
ventional surgical, chemotherapeutic and radiation modalities is these tumors are very in‐
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filtrative. After the neurosurgeons and the radiation oncologists treat their patients, some
remaining cancer  cells  have escaped these  interventions.  Perhaps the  glioma cancer  ini‐
tiating  cells  or  “stem cells”  have  even already migrated into  new areas  of  the  brain  in
searching for  new sources  of  cytokines  or  other  stimuli  (see  Section 6).  There  are  more
components that enable the glioma cells to become more invasive and can become poten‐
tial targets of some therapy.
Glioma  cells  possess  receptors/molecules  than  can  bind  to  environmental  components.
These  receptors  can  be  either  cell-adhesion integrins  or  CD44 [65].  The  most  important
integrins are considered to be the αvβ3, and αvβ5 heterodimers [66]. These integrins act as
receptors to bind vitronectin, fibronectin, osteopontin and cyr61 [67]. The last three ECM
proteins when they were over-expressed also showed a predicted poor survival with glio‐
ma patients. Two other integrins, α6β1 [68] and α5β1 [69], have been reported to also play
roles  in  glioma  tumorigenesis.  The  αvβ3  and  α6β1  integrins  are  functional  receptors  for
several  heparin  binding  growth  factors,  pleiotrophin  and  midkine,  respectively  [70,71].
Midkine has been identified as a potential mediator that promotes chemoresistance with‐
in those midkine-stimulated cells [71].  As described in Table 3 some of these genes that
interacted with the cytokines and growth factors were identified by REMBRANDT as sig‐
nificant  in  predicting  patient  outcome.  REMBRANDT  confirmed  that  CD44,  αv,  α6  and
midkine lead to poorer prognoses.
Cancer cells, including gliomas do release matrix metalloproteineases (MMP) which digest
the surrounding tissue and extracellular matrix allowing the cancer cells to invade sur‐
rounding tissue. By REMBRANDT we identified that MMP1, MMP2, MMP9, MMP11 and
MMP14 all were associated with a bad prognosis. A natural inhibitor of the MMP, called
TIMP3, associated with better patient survival when over-expressed, as current dogma pre‐
dicts. So strategies that counter these MMPs or by increasing TIMP3 activity might have an
important role in preventing the glioma cells from breaking its initial containment.
Gliomas might  also  release  excess  glutamate  and kill  surrounding normal  tissue  via  an
excitotoxic  process  [72].  There  is  speculation  that  gliomas  can  also  down-regulate  their
glutamate receptors [73,74] so that they become impervious to the cytotoxic levels of glu‐
tamate that they release. Glutamate can be synthesized from the enzyme glutamate syn‐
thethese  (GLUL) or  can be  scavenged via  numerous catabolic  pathways.  Glutamate  can
be released via exporters that use K+  and Na+  cation exchangers, or SoLute Carriers (see
Section 7.3 below).  We found that  there was no correlation with GLUL expression with
patient survival or demise. So the most likely source of the released glutamate is coming
via  protein  catabolism.  The  glutamate  receptors  GRIA1,  GRIA2,  GRIA3,  GRIA4,  GRM5
and GRM7 all  correlated with  a  bad prognosis  by  a  REMBRANDT analysis  when they
were down-regulated. The interpretation here is consistent with the initial hypothesis that
this  down-regulation by the glioma cells  can make themselves resistant  to the cytotoxic
levels of glutamate found in the local microenvironment.
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 Figure 7. Electron microscopy of human GBM in situ. Panel A shows gliomas with microvilli invading surrounding ex‐
tracellular matrix: magnified 15,000 x times. Panel B shows gliomas with filopodia invading through other cells. Mag‐
nification 5,000 x times.
7.2. Microvilli and filopodia
Cell surface superstructures including microvilli, invadopodia and filopodia have been
described over the years [75-79]. These structures allow tumor cells to probe for weak spots in
surrounding normal cells and then begin to invade that area as described above. Some of the
gliomas found in GBM do have these microvilli structures in situ. Some microvilli actually had
mitochondria within them (Figure 7A), and their apparent function appears linked with the
ROS generation and subsequent activation of several pathways essentials for glioma inva‐
siveness [80]. Thus, microvilli have a built in power supply to immediately supply the energy
into their probing mechanisms via re-organization of microfilaments and microtubules. At
some edges there were long filopodial projections that could extend past two cell- lengths.
Some glioma cells possess these long filopodia and thus have the ability to probe into distant
sites (Figure 7B). Glioma cells like U251 display her2/neu on their microvilli and filopodia [81].
We have also seen the receptors such as: IL13Ra2, EphA2, EGFR, PDGFR, c-Met, IGFR and
IL6R on the microvilli and filopodia of U251 gliomas [unpublished data]. These microvilli also
provide a novel “sea urchin” type defense that prevents various lymphocytes from mediating
cytotoxicity. Thus these microvilli and filopodia can be used for multiple purposes by glioma
cells and assist in their invasiveness.
We searched out the molecules that have been associated with microvilli, lamellipodia and
filopodia with REMBRANT to identify pathways that are most likely being used by human
gliomas. Figure 8 shows a basic schematic of how these superstructures could be composed
of actin-related proteins Microfilaments, actin-binding proteins and microtubules have been
reviewed in [82-84]. Microfilaments are composed of the actin family members. There are
two types of actin. The monomeric, globular (G-form) represents the single unit, whereas,
when these monomers polymerize, they form the filamentous, F-actin type. Actin contains
both pointed and a barbed ends. The barbed end is protruding from the growing end of the
F-actin polymer. Actin plays many roles in cellular processes. Actin anchors many mem‐
brane-bound proteins in place and are associated with glioma cell motility and the cytoske‐
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leton. Surprisingly, by REMBRANDT, there was no significance of actin expression. So
glioma cells probably just recycle and reuse their actin in a more efficient manner.
Figure 8. Schematic diagram of microvilli/filopodia. The microvilli (left) and a microvilli with a branched filopodia
(right) are shown. Various growth factor/cytokine receptors and cell adhesion molecules are found on these struc‐
tures. Upon binding with their ligands, the transmembrane receptors become activated and allow the nucleation of
various cytoskeletal elements to begin. Hence the activated receptors can now begin a process where cell polarity is
initiated.
There are molecules that crosslink the actin locking proteins together. Some proteins bundle
actin polymers together making these proteins stronger, fascin is a prime example. Actin-
binding proteins like Arp2/3 cause branch points within the polymerized actin strands and
help explain the bending of the filopodia [85]. At least 100 proteins can associate directly or
indirectly with actin some of the more important ones are listed in Table 3. It is therefore not
surprising that actin-binding proteins are associated with the mobility of many cancer cells.
The proteins, fascin, podoplanin, and myosin IIB, have been actively studied with regards to
cancer cell motility [86-90]. These two proteins are also over-expressed in gliomas and in other
cancers. The over-expression of fascin and podoplanin mRNA within gliomas is linked with
a worse prognosis in those patients. Actin and fascin are important for maintaining the
lamellopodia, microvilli and filopodia of various cells (Figure 8). This infiltrative nature of
gliomas is believed to be the prime reason why this tumor remains such a lethal cancer, despite
the best efforts to surgical remove and irradiate the surgical incision sites. So these two
molecules can be considered good targets for possible molecular intervention. Table 3
summarizes as many cytoskeletal elements which have been associated with cell invasion and
migration over the years and correlated them with significance by REMBRANDT.
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Figure 9. Proposed model of ion channel regulation of glioma cell invasion. The main cell body (left) is in normal ionic
homeostasis, where there are high intracellular K+ ion concentrations with relatively low concentrations of Na+ ions.
The invading part of the cell (right) is now swelling as a result of possible activation of several ion channels listed at the
bottom. K+ ions are exported while Na+ and Cl- ions along with water is imported causing the cell swell. As a result of
the swelling at the leading edge the rest of the main cell body can be pulled into the new area. The bottom lines list
the possible ion channels/aquaporins that were identified to be of significance by REMBRANDT.
7.3. A mechanism for glioma cells to squeeze through normal tissue
Harald Sontheimer has pioneered ion channel discovery in brain cancers. His unified hypothe‐
sis is that gliomas can shrink at the leading edge of the glioma cell [91]. In this way, the glioma
cell then behaves like an amoeba and pushes itself through the normal tissue. Figure 9 shows a
simplistic model of the dynamic aspects of ion-driven movements in a slightly different model
19. While at rest and in homeostasis, the glioma cell maintains its normal physiological ionic
composition and has multiple filipodia projections. Some projections find an area which stimu‐
lates proper intracellular interactions and begin an invasive process. Here there is high intracel‐
lular levels of K+, and normal concentrations of Na+, Ca+2, Cl- and water. At the leading edge of
the cell, now a disruption of normal ionic homeostasis occurs. Here K+ channels are activated
and K+ ions are released, while Na+ ions are allowed inside. As Na+ ions enter, so does Cl- anions
and water, hence the cell can expand within this region of the cell. Colman et al., [92] found that
one of the channels that are strongly correlated with poor survival was a CLIC1 chloride chan‐
nel. REMBRANDT confirmed this ion channel expression inversely associated with poor pa‐
tient survival.  This chloride channel, CLIC1, also can share a subunit (BKβ as known as
KCNMB2 or KCNMB3) with the big potassium (BKα, KCNMA1) ion channel channel [93].
REMBRANDT analysis showed the BKβ2 or BKβ3 chains had an inverse correlation with sur‐
vival, like the CLIC1 expression. The KCNMA1/BKα ion channel failed to show any relation‐
ship with glioma patient survival. This last finding prompted us to consider whether other
potassium channels could provide an alternative pathway for exporting of K+ ions instead. The
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potassium channels  are associated with poor glioma survival  are KCNN4, KCNQ1, and
KCNQ4.
For cells to maintain electroneutrality, as K+ ions are eliminated Na+ ions must enter. REM‐
BRANDT analysis reveals that four sodium ion channels are strongly correlated with an ad‐
verse survival rate. These sodium ion channels are TRPM8, TRPM4, TRPV2 and a sodium-
hydrogen exchanger (a.k.a. NHE1, SLC9A1). As sodium ions enter the cell, so does water, so
the aquaporins (water channels) are playing an active role in this dynamic swelling process,
too. The aquaporins, AQP1, AQP5 and AQP9 all show dose-dependent inverse pattern of
survival within glioma patients. Interestingly, AQP7 and AQP10 display an opposite pattern
than the previous three aquaporins. Here over-expression of AQP7 and AQP10 lead to‐
wards better survival, while lowered expression produced a worse prognosis.
Sontheimer’s lab found that a novel spliced version of the BK channel, called the glioma BK
channel is found in human gliomas [94]. We created an antibody directed towards this re‐
gion and confirmed that all human gliomas and many rat and mouse glioma cells lines also
possessed gBK [95]. We also found that two epitopes within these gBK regions can induce
human HLA-A2 restricted CTLs which lyse a variety of human cancer cells including glio‐
ma cells. Thus, ion channels have the potential to be developed into immunotherapeutic tar‐
gets. So the ion channels, CLIC1, KCNMB2, KCNMB3, KCNN4, KCNQ1, KCNQ4, TRPM4,
TRPM8, TRPV2 and SLC9A1 could also theoretically be targeted by immunotherapy. Du‐
troit and colleagues [96] have mapped a HLA-A2 derived peptidome which could stimulate
possible immunotargets for CTL therapy. Some of these identified peptides did include ion
and transporter channels, such as: ATP1A2, ATP2B1, CACNA1A, GRIA2, GRIA3 and
SLC4A4. So immunotherapy might be directed towards these ion channels, aquaporins and
transporters could be playing a role in glioma invasiveness.
7.4. “Death signatures”
Glinsky, et al., [97] analyzed a wide variety of cancers by using microarray technology and
discovered that a series of 11 genes (GBX2, Ki67, CCNB1, BUB1, KNTC2, USP22, HCFC1,
RNF2, ANK3, FGFR2, and CES1) had a unique pattern. When this profile was expressed in
those various cancers it had a high statistical probability that the patient will die of the cancer.
They called this expression pattern, a “Death Signature”. In theory, one would think that if an
immunological intervention could be developed, these gene products might be perfect targets
for immunotherapy, assuming that these genes or their synthesized proteins are actively
playing a role in the cancer’s aggressiveness which leads to the patient’s demise. Since these
genes foretold the patient death, if you could then vaccinate a patient against these antigens
and prevent these genes from manifesting themselves, you should then interfere with their
final outcome, death. When we examined the REMBRANDT survival data with this series of
genes found in the Death Signature, there was actually very little significance; most of the gene
expression patterns, when investigated individually were the opposite of what was predicted
by the Death Signature concept. The only gene that correlated well with poor glioma survival
was a marker for cell proliferation that pathologists regularly use as a sign of cell division,
Ki67. Thus, we feel that this “Death Signature” doesn’t fit too well with gliomas. In fairness to
Glinsky and coworkers, they did use a large variety of cancers and they did do a multigene
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analysis, which REMBRANDT currently does not allow. So any multifactoral effect may have
simply been masked by the complexity of their analysis.
8. Targeting the genes commonly found in human GBM
In 2010, Colman and colleagues reported a series of 31 genes that were associated with poor
GBM survival [92]. When Rembrandt analysis was done using these genes, the vast majority
of these genes correlated extremely well. This evaluation was much better than “Death
Signature profile”. Since the MD Anderson and University of California, San Francisco groups
include many of their patients into REMBRANDT, it would be expected a much better
correlation could be found.
One interesting finding was that a couple of these genes from the Colman, et al. study were
also found in the glioblastoma peptidome derived from HLA-A2 alleles obtained from GBM
surgical specimens [96]. These T cells-derived antigens included: CHI3L1 (YKL-40), IGFBP3
(insulin-like growth factor binding protein-3), PDPN (podoplanin) and TNC (tenascin C). We
further examined these 31 genes from the Colman study and found their protein sequences.
We subjected them to SYPEITHI data analysis program (http://www.syfpeithi.de/) to deter‐
mine the possibility of generating nonomer peptide determinants towards their potential
antigenic peptides. Table 4 summarizes this study. We limited this inquiry to those peptides
that are found restricted to the HLA-0201 allele, since that is the most common HLA allele
found in the US with just a little less than half the Caucasians possessing this phenotype. Some
of the Colman and colleague’s proteins are quite small ranging from 116 amino acids (dynein
light chain) to fibronectin isoform1 that possess 2477 amino acids. For the dynein light chain
there were only 12 predicted peptides that could bind to HLA-A0201 with a binding score of
16 or better. In contrast, the fibronectin isoform-1 had 236 possible peptides. In sum, these
proteins provides 1,802 peptides that could theoretically be used to vaccinate patients against
HLA-0201+ tumor cells. Hence this might provide a particularly rich source of very clinically
relevant antigens to target glioma.
9. New targets
As we have described in Table 1, we only have 17 very good or good tumor antigens by which
we can target brain cancers, thus new antigens are needed. REMBRANDT has validated in
silico that there might be new targets that haven’t been considered before. It will be important
to consider targeting these molecules using a variety of mechanisms since they cause poor
patient survival and their under-expression leads to better survival. This can include immu‐
notherapy, molecular gene silencing or even knock-in strategies to take advantage of those
genes which prolonged patient survival. In Table 2 we show that several growth factors, their
cytokines or their extracellular matrix proteins might be potential good targets. Table 3
illustrated many intracellular cytoskeletal elements that are also good targets for either
Using REMBRANDT to Paint in the Details of Glioma Biology: Applications for Future Immunotherapy
http://dx.doi.org/10.5772/52363
187
immunotherapy or potential gene knock-in. Colman’s study [92] (Table 4) provided an
incredible wealth of potential tumor antigens that could conceivably be targeted.
Growth factor/cytokine Receptor Extracellular protein capable of immobilizing
Acidic Fibroblast growth
factor
FGFR* glypican-1*
Basic Fibroblast growth
factor
FGFR* neurocan, syndecan-1*,-2*,-3, glypican-1*,-2,-3,
phosphacan, nerve-glial antigen-2 (NG2) also known as
chondroiten sulfate proteoglycan 4, phosphacan (PTPRZ1).
Unknown ligand erbB2/her2* not known
Transforming growth factor-
β1**β2**β3
TGFBR1* TGFBR2**
TGFBR3
syndecan-1*, decorin**, dermatan sulfate
Insulin-like growth factor-1 IGF1R glypican-3
Hepatocyte growth factor/ c-Met* dermatan sulfate/chondroiten sulfate B
VEGF-A**, VEGF-B** VEGFR1 (flt1) VEGFR2
(kdr)*
glypican-1*, syndecan-2*
Platelet derived growth
factor-A
PDGFR1 NG2
Platelet derived growth
factor-B*
PDGFR2*
Pleiotrophin* nucleolin, αv*β3 syndecan-3
Α6*β1
Midkine** nucleolin, αv*β3 various heparans
Α6*β1
Neuroregulin-1 erbB3 erbB4 heparan sulfated proteoglycans
Fibroblast growth factor-4 FGFR1 heparan sulfate
SDF-1 (CXCL12) CXCR4* syndecan-4
Epidermal growth factor* EGFR syndecan-2*, laminin A2**, lamininB1**, laminin A5*,
laminin B3*
Interleukin-6* IL6R* not reported yet
Interleukin-8* IL8RA, IL8RB* syndecan-2*
Interleukin-13 IL13Ra1** not reported as yet.
IL13Ra2**
Granulocyte-macrophage CSF2R syndecan-2*
Colony Stimulating Factor c-fms not reported as yet.
Table 2. Growth factors, cytokines and their receptors along with brain derived ECM. Single asterisk indicates either
over-expression leads to poor survival or under-expression leads towards better survival. Double asterisk indicates
both conditions described immediately above were true.
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Thus, targeting some of these genes using DC based vaccines could encompass using whole
tumor cell lysates, recombinant proteins or peptides using this information might be able to
target these key proteins. One can also interfere with these vital functions of glioma invasion
via molecular methods. In support of this concept, Dutroit and colleagues [96] using the
peptidomics approach with HLA-A2 associated peptides has found evidence that some of
these REMBRANDT validated peptides are present and could be possible targets of immuno‐
therapy if one was to use the same starting material that they used.
Signal transduction
Good Potential antigen No relevance Opposite expression
CDC42, grb2, h-ras, n-ras c-Src, Rac1, Raf1, rab4, 5, 8, 11, 21,25 APC, k-ras
Actin Cytoskeletal
Actn, Arf6, basigin, caveolin1, 2,
CDC42, CrkII, diaph1, erm/ moesin,
filamin A, C, fascin1, grb2, gelsolin,
IQGAP1, 2, 3, Mrlc2, Myh9, Nck1,
paxilin, Pdpn, Ppir12a, Pfn1, Rhamm,
supervillin, vimentin, Was/nWasp,
Wasf2
Abi2, Actr3, Arp2, Arp3, Bcar1,
caveolin 3, cofilin, c-Src, Cyfip1,
diaph3, dynamin1, 2, ezrin, f-actin,
fascin2, GFAP, Lmk1, Mena/Enah,
MLCK, Myh2, netrin, Pak1, 3, 4,
profilin 2, RhoA, Sh3pxd2a/Tks5,
Ssh1, vinculin, Wasl, Wipf1
Apc, Aref/ARHGEF4, ARHGEF7,
doublecortin, dynamin3, dock1,
Dtnb, FAK, fascin3, Myh10, Ntn4,
Pak7, Stathmin 2,3, 4, Wasf1
Tubulin cytoskeleton
Kif2c, Kif11/eg5
Dnch2, Dynll2, Dync1l11, Dynein
light chain/tctex, Kif1c, Klc2,
Tubb3,5, Tubg1,2
Kif3c, /kif21b
Membrane Protein
CD44, Itga6, Itgav, Itgb1, Itgb5,
Pdpn, Itgb3
Table 3. Cytoskeletal proteins associated with cell migration, invasion and structure analyzed by REMBRANDT. (+)
indicates significant values, opposite (+) indicates a significant value, but is opposite to what is actually predicted by
current dogma.
REMBRANDT  was  then  used  to  determine  whether  this  gene  is  either  over-expressed
with a bad prognosis or under-expressed with a better survival was. When either one of
those conditions was met then that antigen was considered a potentially good antigen. If
both  conditions  were  met,  then  it  is  considered  a  potentially  very  good  antigen.  Con‐
versely, if neither condition was met then it was considered not good. Opposite indicates
the  REMBRANDT  analysis  contradicts  the  expected  prediction,  where  over  expression
lead to a better survival and vice versa.
The numbers of amino acids of the translated protein are shown. This protein was then
analyzed by SFYPEITHI analysis looking at possible nonamers that can theoretically bind to
HLA-A*0201, as a metric for how tentatively immunogenic this protein could be. SFYPEITHI
scores better than 16 were then counted. REMBRANDT was then used to determine whether
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this gene is either over-expressed with a bad prognosis or under-expressed with a better
survival. When either one of those conditions was met then that antigen was considered a
potentially good antigen. If both conditions were met, then it is considered a potentially very
good antigen. Conversely, if neither condition was met then it was considered not good.
Gene # Amino Acids Predicted #
Epitopes
Rembrandt
Correl
α-actinin-1 isoform a 914 122 Very Good
Aquaporin-1, isoform1 269 66 Very Good
Chitinase-3like protein 1 383 40 Very Good
Chloride intracell. channel protein 1 241 39 Good
Collagen α2 1366 95 Very Good
Epithelial membrane protein-3 163 45 Very Good
Fatty acid binding protein-5 135 14 Very Good
Fibronectin isoform 1 2477 236 Good
Transmembrane glycoprotein NMB 572 77 Very Good
Insulin-like growth factor bind. protein-2 328 41 Very Good
Insulin-like growth factor bind. protein-3 297 33 Very Good
Lactate dehydrogenase A 332 62 Very Good
Galectin-1 135 10 Very Good
Galectin-3 250 23 Very Good
Gycoprotein (transmembrane) NMB 572 44 Very Good
Monoamine oxidase B 520 84 Very Good
Nicotinamide N-methyltransferase 264 38 Very Good
Podoplanin a 238 46 Very Good
Proteolipid protein 2 152 34 Very Good
Transmembrane protein-158 (RIS) 300 50 Very Good
Serpine A3 423 80 Very Good
Plasminogen activator inhibitor 1 402 66 Very Good
Plasma protease C1 inhibitor 500 92 Very Good
Protein S100-A10 97 15 Good
Transgelin 201 21 Very Good
Transgelin 2 199 24 Very Good
Dynein light chain (Tctex) 116 12 No Good
Transforming growth factor-β1 390 57 Very Good
Tissue inhib. Metalloprot inhibitor 1 207 31 Very Good
Thymosin β10 (TMSB10) 44 0 Very Good
Tenascin 2201 179 No Good
VEGF-A 412 28 Very Good
Total Potential T cell epitopes: 1,802
Table 4. SYPEITHI predicted binding epitopes for the genes restricted to HLA-A*0201 that were over-expressed in
glioma and correlated with poor survival.
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10. Limitations and improvements for REMBRANDT
REMBRANDT type databases will be the future analyzing other types of cancer. Overall,
this program is quite useful and easy to use. One must have the proper abbreviation of
the  gene,  which  can  usually  be  found at  websites  like  Gene  Cards,  Wiki  Genes  or  the
HUGO Gene  Nomenclature  Committee  HGNC databases.  Occasionally  for  some  of  the
genes  we  searched,  our  analyses  ran  into  some  technical  problems  that  won’t  perform
the computations,  obviously some glitches remain in the system that  will  be  eventually
ironed out. For the next version of REMBRANDT it will be important to allow the glio‐
ma  sub-classes  to  be  assessed:  proneural,  mesenchymal  and  classic  GBM.  This  option
will  be  important,  since  each  GBM  subclass  has  its  own  particular  targets  to  be  used;
such as growth factor requirements proneural/neural GBM use the PDGF pathway, while
classical GBM use more EGF driven pathways. YKL-40 is a marker of the mesenchymal
GBM subtype and it might be a way to identify key interactions. Multivariant gene anal‐
ysis, where one can analyze several genes simultaneously will also allow better analyses.
So REMBRANDT version 2.0 should be enhanced with this kind of analysis.
The data we analyzed was based on gene expression measuring mRNA levels using microar‐
rays. So the danger is that these conclusions does not necessarily mean that the corresponding
proteins were synthesized. Splice variants are also not taken into account. For example gBK
and BKα channels cannot be distinguished as separate isoform resulted from the current
microarray platform. Nevertheless, this type of analysis will provide neuro-oncologists with
some exciting concepts to think about for years to come.
11. Conclusions
After many frustrating years of attempting to use immunotherapy against cancers, tumor
immunologists are starting to see successful results in melanomas, prostate cancer and in some
GBM patients including high grade gliomas. The identification of better glioma-associated
antigens is paramount to continue this investigative process. Many defined antigens have been
discovered by serendipity and this random process has lead to developments such as using a
variety of modalities: immunotoxins, chimeric antigen re-directed T cells, molecular silencing
approaches, DC-based vaccines, etc. But there are undoubtedly many more antigens still to be
discovered. Microarray analysis of tumors has already been proven to be a powerful way of
classifying tumors and provide novel tumor-specific therapies. The REMBRANDT data portal
allows researchers a chance to quickly assess this microarray data and quickly test potential
therapies in silico as we have attempted to do here before doing expensive clinical trials.
REMBRANDT gives one a chance to determine whether a gene has any importance in glioma
biology using a large data base. In this chapter we showed that REMBRANDT offers oncolo‐
gists a chance to analyze various biological pathways to see if predicted molecules seen in
tissue culture cell lines are applicable with the in situ scenario. REMBRANDT offers immu‐
nologists a chance to now make use of the key genes involved in gliomas and then target them
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for immunotherapy. By targeting critical genes by therapy, one hopes to attack cancers at their
strong points. REMBRANDT is pioneering this ability and its ability will undoubtedly will be
copied by other medical oncologists in studying their cancer of interest. So this is the first step
towards using knowledge to specifically target cancer.
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